Jill Ann Howe Net Worth

The estimated Net Worth of Jill Ann Howe is at least $9.24 Tausend dollars as of 16 August 2024. Jill Howe owns over 10,500 units of Progenity stock worth over $9,240 and over the last 3 years Jill sold PROG stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jill Howe PROG stock SEC Form 4 insiders trading

Jill has made over 1 trades of the Progenity stock since 2024, according to the Form 4 filled with the SEC. Most recently Jill bought 10,500 units of PROG stock worth $9,345 on 16 August 2024.

The largest trade Jill's ever made was buying 10,500 units of Progenity stock on 16 August 2024 worth over $9,345. On average, Jill trades about 2,100 units every 0 days since 2021. As of 16 August 2024 Jill still owns at least 10,500 units of Progenity stock.

You can see the complete history of Jill Howe stock trades at the bottom of the page.

What's Jill Howe's mailing address?

Jill's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.

Insiders trading at Progenity

Over the last 4 years, insiders at Progenity have traded over $0 worth of Progenity stock and bought 34,001,547 units worth $176,045,049 . The most active insiders traders include Capital Management, Lp Ferr..., Opportunities Fund (A) Lp A... und Opportunities Fund (A) Lp A.... On average, Progenity executives and independent directors trade stock every 24 days with the average trade being worth of $1,994,758. The most recent stock trade was executed by Capital Management, Lp Ferr... on 14 June 2021, trading 8,097,166 units of PROG stock currently worth $20,000,000.

What does Progenity do?

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Complete history of Jill Howe stock trades at Lineage Cell Therapeutics Inc und Progenity

Progenity executives and stock owners

Progenity executives and other stock owners filed with the SEC include:

• Eric d'Esparbes,
  Chief Financial Officer
• Damon Silvestry,
  Chief Operating Officer
• Robyn Hatton,
  VP of HR
• George Gianakopoulos,
  Sr. VP of Sales
• Hutan Hashemi J.D.,
  Chief Compliance Officer
• Clarke Neumann,
  Sr. VP, Gen. Counsel & Sec.
• Troy Seelye,
  Chief Information Officer
• Dr. Matthew T. Cooper M.B.A., Ph.D.,
  Chief Scientific Officer
• Eric Fox,
  VP of Fin. & Accounting & Treasurer
• Aditya P. Mohanty,
  CEO & Director
• Jill Ann Howe,
  Director
• Surbhi Sarna,
  Director
• Hutan Hashemi,
  Chief Compliance Officer
• Eric D Esparbes,
  Chief Financial Officer
• Clarke Neumann,
  See Remarks
• Harry Stylli,
  Chairman & CEO
• Opportunities Fund (A) Lp A...,
  
• Capital Management, Lp Ferr...,
  
• Troy Seelye,
  Chief Information Officer
• Sami Shihabi,
  Chief Commercial Officer
• George Gianakopoulos,
  Senior Vice President of Sales
• Jeffrey D. Alter,
  Director
• Capital Management, Lp Ferr...,
  
• Samuel R Md Nussbaum,
  Director
• Lynne Powell,
  Director
• Opportunities Fund (A) Lp A...,
  
• John T. Bigalke,
  Director
• Brian L. Kotzin,
  Director
• Damon Silvestry,
  See Remarks
• Aditya P. Mohanty,
  Chief Executive Officer
• Matthew T Cooper,
  General Manager, Diagnostics